CANY
TGTX icon

Caxton Associates (New York)’s TG Therapeutics TGTX Stock Holding History

Caxton Associates (New York)’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$498K Hold
16,557
– – 0.02% 330
2024
Q3 		$387K Buy
+16,557
New +$362K 0.01% 402
2022
Q3 		– Sell
-68,677
Closed -$292K – 667
2022
Q2 		$292K Buy
+68,677
New +$429K 0.03% 393

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Caxton Associates (New York)'s TGTX Position: Q4 2024 in Review

Caxton Associates (New York) held its TG Therapeutics (TGTX) position steady in Q4 2024 at 16,557 shares worth $498K. The position accounts for 0.02% of the portfolio, ranked #330.

Caxton Associates (New York) first reported a position in TGTX in Q2 2022 and has held it in 3 quarters since. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Caxton Associates (New York) held 16,557 shares of TG Therapeutics worth $498K as of Q4 2024.
  • Caxton Associates (New York) left its TG Therapeutics share count unchanged in Q4 2024.
  • TG Therapeutics made up 0.02% of Caxton Associates (New York)'s portfolio in Q4 2024, its #330 holding.
  • Caxton Associates (New York) first reported a position in TG Therapeutics in Q2 2022 and has held it in 3 quarters since.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.